Research programme: human papillomavirus vaccine - Biotech Australia/University of Queensland
Latest Information Update: 30 May 2007
Price :
$50 *
At a glance
- Originator Biotech Australia; The University of Queensland
- Class
- Mechanism of Action Helper-inducer T-lymphocyte modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cervical cancer
Most Recent Events
- 18 Nov 2002 No development reported - Preclinical for Cervical cancer in Australia (Parenteral)
- 18 May 1999 A study has been added to the adverse events section and the Viral Infections immunogenicity section
- 14 Sep 1998 Phase-I clinical trials for Cervical cancer in USA (Parenteral)